Prospects for a dengue virus vaccine

SS Whitehead, JE Blaney, AP Durbin… - Nature Reviews …, 2007 - nature.com
The number of cases of severe dengue disease continues to grow in endemic areas of
southeast Asia, Central and South America, and other subtropical regions. Children bear the …

A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available

T Ishikawa, A Yamanaka, E Konishi - Vaccine, 2014 - Elsevier
Genus flavivirus comprises many important human pathogens causing public health
problems worldwide. Some flavivirus infections are characterized by a relatively high …

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised …

JE Osorio, ID Velez, C Thomson, L Lopez… - The Lancet Infectious …, 2014 - thelancet.com
Background Dengue virus is the most serious mosquito-borne viral threat to public health
and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent …

Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development

A Wilder-Smith, EE Ooi, SG Vasudevan… - … infectious disease reports, 2010 - Springer
Dengue virus is the most widespread geographically of the arboviruses and a major public
health threat in the tropics and subtropics. Scientific advances in recent years have provided …

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

JE Osorio, CYH Huang, RM Kinney, DT Stinchcomb - Vaccine, 2011 - Elsevier
Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is
being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we …

A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults

D Morrison, TJ Legg, CW Billings… - The Journal of …, 2010 - academic.oup.com
Abstract Background. Sanofi Pasteur has developed a tetravalent dengue vaccine (TDV)
against the world's most common arbovirus infection. Methods. We assessed the safety and …

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

BAG Coller, DE Clements, AJ Bett, SL Sagar… - Vaccine, 2011 - Elsevier
Challenges associated with the interference observed between the dengue virus
components within early tetravalent live-attenuated vaccines led many groups to explore the …

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

RZ Capeding, IA Luna, E Bomasang, S Lupisan… - Vaccine, 2011 - Elsevier
A recombinant live attenuated tetravalent dengue vaccine (TDV) is safe and immunogenic in
adults and children in dengue-naïve populations. Data are needed in dengue endemic …

[HTML][HTML] Anti-dengue vaccines: from development to clinical trials

JR Pinheiro-Michelsen, RSO Souza… - Frontiers in …, 2020 - frontiersin.org
Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are
responsible for the infectious disease called dengue that annually affects nearly 400 million …

Dengue vaccines: progress and challenges

BAG Coller, DE Clements - Current opinion in immunology, 2011 - Elsevier
With several dengue vaccine candidates progressing through clinical trials, several options
for controlling this disease appear feasible. This would represent a major achievement and …